Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature

@article{Massey2014TyrosineKI,
  title={Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature},
  author={Paul R. Massey and Jonathan S. Okman and Julia Wilkerson and Edward West Cowen},
  journal={Supportive Care in Cancer},
  year={2014},
  volume={23},
  pages={1827-1835}
}
Inhibition of the vascular endothelial growth factor receptor (VEGFR) with tyrosine kinase inhibitors (TKIs) is associated with cutaneous adverse effects that increase patient morbidity. Our objective was to examine the skin toxicity profile of anti-VEGFR TKIs and determine the changing incidence in clinical trials. PubMed was queried for phase II or III… CONTINUE READING